For a decade, “hot-spotting” was the closest thing population health had to a hero story: find the sickest, most expensive patients, wrap them in intensive care coordination, and watch the readmissions fall. Then someone ran a randomized controlled trial — and the readmissions didn’t fall.
That result is one of the most important and most misunderstood findings in complex care, and it changes how you should think about identification.
1. What the trial found
180-day readmission rate: 62.3% in the intervention group, 61.7% in the control group. No meaningful difference.
The Camden Coalition’s care-management model targeted true super-utilizers — patients with multiple recent hospitalizations and multiple chronic conditions — with an intensive, multidisciplinary team in the 90 days after discharge. In 2020, a randomized controlled trial of 800 such patients, published in the New England Journal of Medicine, found essentially no difference in 180-day readmissions between the program and usual care.
This wasn’t a weak program or a small study. It was a rigorous test of the most celebrated model in the field — and it came up empty on its primary outcome.
2. The trap the whole field had fallen into
When you select patients because they’re at their most extreme, they tend to drift back toward normal on their own.
Here is the lesson that matters most. Patients get enrolled in these programs at their sickest, most expensive moment — right after a string of admissions. Statistically, many were going to improve somewhat no matter what, simply through regression to the mean.
Observational studies couldn’t see that. They enrolled high-utilizers, watched utilization fall, and credited the program. The randomized trial stripped the illusion away by comparing against a control group that regressed to the mean too. Much of what looked like program impact was just patients returning to baseline.
3. What actually failed — and what didn’t
Follow-up research told a more nuanced story. The program did improve intermediate care coordination — it increased post-discharge ambulatory visits, driven by primary care. It did the coordination work it promised. It just didn’t translate that into fewer readmissions for this population.
The conclusion the researchers drew is sharp: for the most medically and socially complex patients, care coordination alone may not be enough to change hospitalization. The drivers — poverty, housing, addiction, fragmented systems — sit deeper than a 90-day care team can reach.
4. The engagement signal hiding in the data
A later secondary analysis found something important: among the patients most likely to actually engage with the program, readmissions did fall. The intervention wasn’t inert — it worked for the subset that participated.
That points straight back to impactability. The problem was never that care management can’t help anyone. It’s that targeting people by raw utilization — rather than by who can actually be reached and moved — dilutes the effect until a trial can’t detect it.
5. What to take from it
Three practical lessons. First, distrust your own before-and-after numbers; if you enrolled patients at their peak, regression to the mean is inflating your reported wins. Second, identifying high-utilizers is the beginning of the work, not the end — targeting, engagement, and intervention design decide whether anything changes. Third, for the most complex patients, expect that coordination alone won’t move outcomes without addressing the social and behavioral drivers underneath.
None of this means give up on complex care. It means do it with clear eyes about what the evidence actually shows.
Final Thoughts
The Camden result was painful precisely because the model was so intuitively right. That’s what makes it valuable: it’s a rare case where the field got to check its intuition against a real experiment and learn something uncomfortable.
As someone trained as a physician who moved into analytics and strategy, I keep this study close because it enforces humility. Finding the sickest patients feels like the hard part. It isn’t. Knowing who you can actually help, and how, is the hard part — and the evidence says most programs are still guessing at it.
If your care-management results rest on before-and-after utilization numbers, some of your “impact” is regression to the mean. At HealtheNomics I help organizations move from raw high-utilizer targeting to impactability- and engagement-based identification — so the effect is real enough to survive scrutiny.
Explore the services: https://healthenomics.com/services-2/
Request a strategy conversation: https://healthenomics.com/contact-us/
Connect on LinkedIn: https://www.linkedin.com/in/muhammad-ayoub-ashraf/
Website: https://www.drayoubashraf.com
Watch on YouTube: https://www.youtube.com/@HealtheNomics
